Opthea Advances nAMD Treatment with Sozinibercept
PremiumCompany AnnouncementsOpthea Advances nAMD Treatment with Sozinibercept
2M ago
Opthea completes drug substance PPQ campaign for sozinibercept
Premium
The Fly
Opthea completes drug substance PPQ campaign for sozinibercept
2M ago
Opthea Advances Toward Sozinibercept Commercialization
Premium
Company Announcements
Opthea Advances Toward Sozinibercept Commercialization
2M ago
Opthea Prepares for Phase 3 Results with Leadership Revamp
PremiumCompany AnnouncementsOpthea Prepares for Phase 3 Results with Leadership Revamp
3M ago
Opthea announces executive leadership changes and senior hires
Premium
The Fly
Opthea announces executive leadership changes and senior hires
3M ago
Opthea Limited Showcases Innovations at Investor Conferences
Premium
Company Announcements
Opthea Limited Showcases Innovations at Investor Conferences
3M ago
Opthea forms Medical Advisory Board with retinal disease experts
PremiumThe FlyOpthea forms Medical Advisory Board with retinal disease experts
4M ago
Opthea completes 1 for 1.22 accelerated non-renounceable entitlement offer
Premium
The Fly
Opthea completes 1 for 1.22 accelerated non-renounceable entitlement offer
4M ago
Opthea announces publication on VEGF-C, VEGF-D signaling pathways
Premium
The Fly
Opthea announces publication on VEGF-C, VEGF-D signaling pathways
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100